Nubratori, Inc. Initiates Class II Recall for Dexonto 0.4% Due to Critical Labeling Error
Nubratori, Inc. has initiated a Class II recall for its Dexonto 0.4% (dexamethasone sodium phosphate) solution due to an incorrect expiration date on outer packaging. This voluntary, firm-initiated action impacts 20 boxes distributed in PA and CA, highlighting the critical need for stringent labeling controls to prevent patient safety risks and ensure regulatory compliance.
Nubratori's Dexonto 0.4% Recall: Critical Labeling Discrepancy and Regulatory Implications
Nubratori, Inc., based in Torrance, CA, has initiated a Class II voluntary recall for its Dexonto 0.4% (dexamethasone sodium phosphate) solution, a non-sterile product intended exclusively for iontophoresis use. This action, identified by recall number D-0392-2025 and initiated on April 15, 2025, stems from a significant labeling error concerning the product's expiration date. While individual 5 mL single-dose vials of Dexonto 0.4% correctly display a Beyond Use Date (BUD) of December 25, 2024, the outer boxes for certain units of Lot #: C04292401X1 were incorrectly labeled with a BUD of December 25, 2025. This discrepancy affects 20 boxes of the product, each containing 12 vials, and distributed across Pennsylvania and California. For procurement directors and regulatory affairs heads, this event underscores the critical importance of meticulous label control and verification processes within pharmaceutical manufacturing. An incorrect expiration date can lead to the inadvertent use of an expired product, potentially compromising patient treatment efficacy or safety, particularly for a specialized formulation like Dexonto 0.4% (NDC 71300-6564-1 for the box, 71300-6564-3 for the vial). The FDA's classification of this as a Class II recall indicates that the use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates immediate action from any entity involved in the distribution or dispensing of this specific lot.
Operational Context: Nubratori, Inc.'s Product Specifics and Market Reach
The recalled product, Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 mg/mL), is a specialized, preservative-free formulation indicated for iontophoresis use only, explicitly noting it is not for injection. This specificity means its primary users are likely clinics, hospitals, or specialized medical practices utilizing iontophoresis for drug delivery. The recall, initiated by Nubratori, Inc. from its Torrance, CA facility (postal code 90501-7220), highlights the need for robust quality assurance even for niche pharmaceutical products. With a limited quantity of 20 boxes affected and distribution confined to Pennsylvania and California, the immediate supply chain disruption is contained. However, for business development executives, this incident serves as a reminder that even localized quality control issues can impact brand trust and necessitate proactive communication with downstream partners. The 'Voluntary: Firm initiated' nature of the recall suggests Nubratori, Inc. identified the error and took corrective action, but the ongoing status of the recall (as of May 7, 2025) means that affected product may still be in the supply chain. Supply chain VPs must ensure their systems can rapidly identify and isolate specific lots, particularly for products with unique administration methods and limited distribution, to manage recall logistics efficiently and minimize patient risk.
Proactive Compliance: Lessons for Pharmaceutical Labeling and Quality Control
This Dexonto 0.4% recall by Nubratori, Inc. offers critical insights for all stakeholders in the global chemical and life sciences industry, particularly for regulatory affairs heads and procurement directors. The fundamental issue—an incorrect expiration date on outer packaging versus individual vials—underscores the absolute necessity of stringent quality management systems (QMS) and multi-layered label verification processes. Even a seemingly minor discrepancy can lead to a Class II recall, incurring significant costs related to product retrieval, potential reputational damage, and the diversion of resources. Companies should evaluate their current label generation, printing, and application procedures, ensuring independent checks and balances are in place to catch such errors before products reach distribution. This includes implementing automated vision systems and manual double-checks for critical data points like lot numbers and expiration dates. Furthermore, the incident reinforces the FDA's unwavering focus on data integrity and accuracy in all aspects of drug manufacturing and labeling. Proactive investment in robust QMS, comprehensive employee training, and continuous process improvement are not merely regulatory requirements but essential business imperatives. Failure to maintain impeccable labeling accuracy can lead to more severe regulatory actions, broader market withdrawals, and significant commercial setbacks, impacting customer confidence and long-term market access.